Journal of Hepatology
Volume 56, Issue 2 , Pages 374-380 , February 2012

Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing

  • Einar Björnsson

      Affiliations

    • Department of Internal Medicine, Section of Gastroenterology and Hepatology, The National University Hospital, Reykjavik, Iceland
    • Corresponding Author InformationCorresponding author. Address: The National University Hospital, 101 Reykjavik, Iceland.
    • ,
  • Elin I. Jacobsen

      Affiliations

    • Department of Internal Medicine, Section of Gastroenterology and Hepatology, The National University Hospital, Reykjavik, Iceland
    • ,
  • Evangelos Kalaitzakis

      Affiliations

    • Institute of Internal Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Received 19 April 2011 ,Revised 8 July 2011 ,Accepted 26 July 2011.

References 

  1. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1999;151(1):43–49
  2. Wright RA, Flapan AD, McMurray J, Slattery J, White HD, Spaulding C, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(19):1383–1389
  3. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–1718
  4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–1307
  5. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22:145–155
  6. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126(5):1287–1292
  7. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004;174(1):193–196
  8. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008 Dec;57(12):1711–1718
  9. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol. 2007;47(1):135–141
  10. Athyros VG, Tziomalos K, Gossios KD, Griva D, Anagnostis P, kargiotis K, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010;376:1916–1922
  11. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010;105(5):978–980
  12. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Review. Semin Liver Dis. 2009;29(4):412–422
  13. Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis. 2006;38(10):772–777
  14. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806–815
  15. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–1330
  16. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–1336
  17. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42(2):481–489
  18. Karnik N, Maldonado J. Antidepressants and statin interactions: a review and case report og simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics. 2005;46:565–568
  19. Preston R, et al. A ranomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: The respond trial. J Clin Pharmacol. 2007;47:1555–1569
  20. Sawant R. Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin. Can J Clin Pharmacol. 2009;16:e78–e79
  21. Alsheikh-Ali A, Abourjaily H, Karas R. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin and acarbose). Am J Cardiol. 2002;89:1308–1310
  22. Hansten P, Horn J. Drug interactions analysis and management. St. Louis, Missouri: Wolters Kluwer Health, Inc.; 2008;
  23. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41:690–695
  24. Bader T. Liver tests are irrelevant when prescribing statins. Lancet. 2010;376(9756):1882–1883
  25. Davern TJ, Chalasani N. Drug-induced liver injury in clinical trials: as rare as hens’ teeth. Am J Gastroenterol. 2009;104(5):1159–1161
  26. Senior J. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis. 2007;11:507–524
  27. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Spanish Group for the Study of drug-induced liver disease. Gastroenterology. 2005;129:512–521
  28. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Drug Induced Liver Injury Network (DILIN). Gastroenterology. 2008;135:1924–1934
  29. Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003;39(6):1095–1097
  30. Sreenarasimhaiah J, Shiels P, Lisker-Melman M. Multiorgan failure induced by atorvastatin. Am J Med. 2002;113:348–349
  31. Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM, Selvaggi G, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy. 2008;28:1188–1193
  32. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–1023
  33. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology. 2010;52(6):2065–2076
  34. Law MR, Rudnicka AR. Statin safety: evidence from the published literature. Am J Cardiol. 2006;97(Suppl. 8A):52C–60C
  35. Tolman KG. Reply to Dr. Dujovnes editorial. Am J Cardiol. 2002;89:1451
  36. Cohen DE, Ananina FA, Chalasani N. An assessment of statin therapy by hepatologists. Am J Cardiol. 2006;97(Suppl.):77C–81C
  37. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498–511
  38. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010 Jun;51:2117–2126
  39. Miljkovic MM, Dobric S, Dragojevic-Simic V. Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. Pharmacoepidemiol Drug Saf. 2011;20:272–285

PII: S0168-8278(11)00658-1

doi: 10.1016/j.jhep.2011.07.023

Journal of Hepatology
Volume 56, Issue 2 , Pages 374-380 , February 2012

Article Tools

* Image Usage & Resolution